Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Toplak Hermann |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Innerhofer, R; Ebenbichler, C; Baumgartner-Kaut, M; Esterbauer, H; Fasching, P; Ferch, M; Galli, L; Greber-Platzer, S; Grohs, K; Harreiter, J; Karall, D; Kleemann, L; Klein, D; Krychtiuk, K; Mäser, M; Rega-Kaun, G; Scholl-Bürgi, S; Schwaiger, E; Speidl, W; Stulnig, T; Stögerer-Lanzenberger, M; Sunder-Plassmann, R; Toplak, H; Widhalm, K; Witsch-Baumgartner, M; Winhofer, Y; Dieplinger, J; Binder, C
VARIANT-SPECIFIC LDL-CHOLESTEROL PATTERNS AND RISK OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN HETEROZYGOUS FH: INSIGHTS FROM THE AUSTRIAN FH-REGISTRY
ATHEROSCLEROSIS. 2024; 395: -Annual Meeting EAS 2024; May 26-29; Lyon.
[Poster]
Web of Science
Innerhofer, R; Ebenbichler, C; Baumgartner-Kaut, M; Esterbauer, H; Fasching, P; Ferch, M; Galli, L; Greber-Platzer, S; Höllerl, F; Huber, K; Karall, D; Kleemann, L; Ludvik, B; Mäser, M; Rega-Kaun, G; Scholl-Buergi, S; Speidl, W; Stulnig, T; Stögerer-Lanzenberger, M; Toplak, H; Widhalm, K; Winhofer-Stöckl, Y; Witsch-Baumgartner, M; Dieplinger, H; Binder, C
CHARACTERISTICS AND MANAGEMENT OF INDIVIDUALS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN AUSTRIA - DATA FROM THE NATIONAL FH-REGISTRY
ATHEROSCLEROSIS. 2023; 379: S115-S115.-91st Annual Meeting of the European-Atherosclerosis-Society (EAS); MAY 21-24, 2023; Mannheim, GERMANY.
[Poster]
Web of Science
Moissl, A; Lorkowski, S; Meinitzer, A; Pilz, S; Scharnagl, H; Delgado, G; Kleber, M; Krämer, B; Pieske, B; Grübler, M; Brussee, H; Von Lewinski, D; Toplak, H; Fahrleitner-Pammer, A; März, W; Tomaschitz, A
HEAT FAILURE WITH PRESERVED EJECTION FRACTION. ASSOCIATION OF BRANCHED-CHAIN AMINO ACIDS WITH MORTALITY RISK IN THE LUDWIGSHAFEN RISK AND CARDIOVASCULAR HEALTH (LURIC) STUDY
ATHEROSCLEROSIS. 2023; 379: S140-S140.-91st Annual Meeting of the European-Atherosclerosis-Society (EAS); MAY 21-24, 2023; Mannheim, GERMANY.
[Poster]
Web of Science
Ray, K; Aguiar, C; Arca, M; Connolly, D; Eriksson, M; Ferrieres, J; Laufs, U; Mostaza, J; Nanchen, D; Blackburn, C; Soronen, J; Lamparter, M; Rietzschel, E; Strandberg, T; Toplak, H; Visseren, F; Catapano, A
LIPID MANAGEMENT IN PATIENTS WITH HIGH AND VERY HIGH CARDIOVASCULAR RISK: DATA FROM ROUTINE CLINICAL PRACTICE IN EUROPE (SANTORINI STUDY)
ATHEROSCLEROSIS. 2023; 379: -91st Annual Meeting of the European-Atherosclerosis-Society (EAS); MAY 21-24, 2023; Mannheim, GERMANY.
[Poster]
Web of Science
Ebenbichler, C; Toplak, H; Drexel, H; Hanusch, U; Bridges, I; Dhalwani, N; Hemetsberger, M; Pigard, N
Final results of the Austrian cohort of the pan-European observational study -HEYMANS
WIEN KLIN WOCHENSCHR. . 2022; 134(SUPPL 4):239-240.-ÖDG Jahrestagung; Nov 17-19, 2022; Salzburg.
[Poster]
Web of Science
Gütl, K; Leitner, DR; Avian, A; Beck, A; Rabensteiner, J; Raggam, RB; Toplak, H; Gary, T
Anticoagulation with direct oral factor-Xa-inhibitors in the obese: do body weight and body composition matter?
Doctoral Day; FEB 10; Graz, AUSTRIA. 2022.
[Onlinepräsentation]
Gütl, K; Leitner, DR; Avian, A; Rabensteiner, J; Beck, A; Raggam, RB; Toplak, H; Gary, T
Anticoagulation with direct oral factor-Xa-inhibitors in the obese: do body weight and body composition matter? A prospective pilot study
GTH; MAR 1-4, 2022; Leipzig. 2022.
[Poster]
Lackner, S; Mörkl, S; Winkler, A; Toplak, H; Roller-Wirnsberger, R; Holasek, SJ
Implementation of nutrition education in the medical school of Graz, Austria. Self-perception of clinical nutrition knowledge among medical students - preliminary result.
ESPEN Congress on Clinical Nutrition and Metabolism; SEPT 3-6, 2022; Vienna, AUSTRIA. 2022.
[Poster]
Ebenbichler, C; Drexel, H; Hanusch, U; Hemetsberger, M; Pigard, N; Toplak, H
Evolocumab in clinical Practice in Austria: Interim Data on LDL-C Goal Attainment from the European non-interventional HEYMANS Study
WIEN KLIN WOCHENSCHR. 2021; 133(SUPPL 6):203-204.-ÖDG Jahrestagung; Nov 18-20, 2021; Salzburg/WEB.
[Poster]
Web of Science
Metzner, T; Leitner, DR; Dimsity, G; Gunzer, F; Opriessnig, P; Mellitzer, K; Beck, A; Sourij, H; Stojakovic, T; Deutschmann, H; Arz, WM; Landmesser, U; Brodmann, M; Reishofer, G; Scharnagl, H; Toplak, H; Silbernagel, G
SHORT-TERM EFFECTS OF INTENSIVE LDL-CHOLESTEROL LOWERING WITH ALIROCUMAB ON VASCULAR STRUCTURE AND FUNCTION
ATHEROSCLEROSIS. 2021; 331: E228-E228.
[Poster]
Web of Science
Ebenbichler, C; Drexel, H; Hanusch, U; Hemetsberger, M; Holzl, R; Toplak, H
Evolocumab in clinical Practice in Austria: Interim Data on the Achievement of LDL-C-Target Values from the European, non-interventional HEYMANS-Study.
WIEN KLIN WOCHENSCHR. 2020; 132: S342-S342.
[Poster]
Web of Science
Banzer, W; Berg, A; Braumann, KM; Führer Sakel, D; Halle, M; Martin, S; McCarthy, D; Prelle, HG; Scholze, J; Seyller, C; Toplak, H
One year effects of the ACOORH concept on weight control and metabolic regulation: results of a Multicenter RCT in ea real world setting reveal significance and gender differences
Obesity Facts. 2019; 12(Suppl1):3-4.-26th European Congress on Obesity (ECO 2019); April 28 - May 1, 2019; Glasgow. (ISBN: 978-3-318-06510-7 )
[Oral Communication]
Ebenbichler, C; Kedenko, L; Hanusch, U; Sourij, H; Drexel, H; Prager, R; Hemetsberger, M; Ratzinger, M; Toplak, H
Evolocumab in clinical Practice in Austria in Comparison to Total Evaluation from 10 Countries: 12-Month Interim Data
WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5):S465-S466.
[Poster]
Web of Science
Guttmann, A; Horist-Kollmann, SM; Prenner, C; Deutsch, A; Kristoferitsch, M; Krautsack, A; Wappl, E; Thauerer, WKB; Toplak, H; Strametz-Juranek, J
Malnutrition - Influence and Outcome in cardiovascular Rehabilitation: Pilot Study
WIEN KLIN WOCHENSCHR. Abstracts, Österreichische Kardiologische Gesellschaft Jahrestagung 2019,
mit Beteiligung der Österreichischen Gesellschaft für Herzchirurgie und thorakale Gefäßchirurgie.. 2019; 131: 298-299.
[Poster]
Web of Science
FullText
Paumann, R; Moyses, K; Toplak, H
Does the Completion of the 6-to 9-month Program "Vorsorge Aktiv - Lebensstilmedizin" lead to a Change in Performance that can be proven in Ergometer Tests?
WIEN KLIN WOCHENSCHR. Abstracts 47. Jahrestagung der Österreichischen Diabetes Gesellschaft. 2019; 131(SUPPL 5):S461-S461.-47. Jahrestagung der Österreichischen Diabetes Gesellschaft; NOV 21-23, 2019; Salzburg, Austria.
[Poster]
Web of Science
Drexel, H; Toplak, H; Hanusch, U; Prager, R; Sourij, H; Hemetsberger, M; Ratzinger, M; Ebenbichler, C
Evolocumab in clinical Practice in Austria: 6 Months Interim Data on Patient Characteristics, Efficacy and Tolerability from a European, non-interventional Study
WIEN KLIN WOCHENSCHR. 2018; 130: 359-360.
[Poster]
Web of Science
Berg, A; Koohkan, S; Banzer, W; Braumann, KM; Fuhrer-Sakel, D; Halle, M; Martin, S; Predel, HG; Toplak, H
THE ALMASED CONCEPT AGAINST OVERWEIGHT AND OBESITY AND RELATED HEALTH RISK (ACOORH)-FIRST RESULTS OF AN INTERIM ANALYSIS
DIABETES TECHNOL THE. 2016; 18: A131-A132.
[Poster]
Web of Science
Berg, A; Kookhan, S; Halle, M; Martin, S;Prevel, H; Toplak, H
The ACOORH concept against overweight and obesity and related health risk - results on weight control and metabolic regulation after 12 weeks of intervention.
Obesity Facts. 2016; 9(Supp 1):259-259.-European Obesity Summit; June 1-4; Göteborg, SWEDEN. (ISBN: 978-3-31805895-6 )
[Poster]
FullText
Berg, A; Koohkan, S; Kempf, K; Martin, S; McCarthy, D; Toplak, H
THE ALMASED CONCEPT AGAINST OVERWEIGHT AND OBESITY AND RELATED HEALTH RISK (ACOORH) HAS STARTED
DIABETES TECHNOL THE. 2015; 17: A141-A142.
[Poster]
Web of Science
Geil, S; Sendlhofer, G; Toplak, H; Pregartner, G; Pail, E
Feasibility trial to assess the patient safety culture in the professional group of dietitians
Safety in Health, Supplement 1. 2015; Volume 1(1):1-19.-Sicherheit im Krankenhaus: Von der Strategie zur Umsetzung; Sep 29-30, 2015; Graz, AUSTRIA.
[Poster]
FullText
Toplak, H
State of the art in weight management.
52th ERA-EDTA Congress; May 28-31; London, UK. 2015.
[Oral Communication]
FullText
Toplak, H
Conferencia inaugural: The Milan Declaration and its consequences for Obesity in Europe.
12th SEEDO (Spanish national Obesity Meeting); November 25-27; Malaga. 2015.
[Keynote lecture]
FullText
Brath, H; Ebenbichler, C; Paulweber, B; Toplak, H; Prager, R; Ludvik, B
Impact of hypoglycaemia on patient actions in the Austrian hypoglycaemia assessment tool (HAT) study cohort
WIEN KLIN WOCHENSCHR. 2014; 126: S186-S186.
[Poster]
Web of Science
Gäbler, G; Toplak, H; Hefti, R; Haas, J; Pail, E.
Association between health behavior and religion/spirituality in adolescents. A cross sectional survey of Austrian High Schools.
Conference book. 2014; 45-46.-European Conference on Religion, Spirituality and Health; May 22-24; Malta.
[Oral Communication]
FullText
Grabner-Ostermann, A; Sendlhofer, G; Toplak, H; Pail, E
Qualitätsmanagement im Bereich der Diätologie. Kann diätologische Leistung messbar gemacht werden ?
http://www.fh-joanneum.at/aw/home/Studienangebot_Uebersicht/department_gesundheitsstudien/nut/Forschung_Entwicklung/~cqus/Kongressbeitraege/?lan=de. 2014; -31. Ernährungskongress des Verbandes der Diätologen Österreichs ; Mar 27-28, 2014; Wien.
[Oral Communication]
Kosi, J; Tinchon, C; Toplak, H; Pail, E
Orale Fettzufuhr während des stationären Aufenthaltes bei Patienten unter Posaconazol.
2014; -31. Ernährungskongress des Verbandes der Diätologen Österreichs; Mar 27-28, 2014; Wien.
[Oral Communication]
Kosi, J; Tinchon, C; Toplak, H; Pail, E
Orale Fettzufuhr während des stationären Aufenthaltes bei Patienten unter Posaconazol.
2014; -Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie (ÖGHO) & der Arbeitsgemeinschaft hämato- ontologischer Pflegepersonen (AHOP); Apr 10-12, 2014; Innsbruck.
[Poster]
Kugel, E; Treiber, G; Toplak, H; Pail, E
Der Einfluss des Ernährungsverhaltens morbid adipöser Personen auf das Gewicht und Komplikationen nach einer Roux-en-Y Magenbypass-Operation.
http://www.obesity-online.com/expertmeeting/. 2014; -12th International Expert Meeting for the Surgery of Obesity and Metabolic Disorders; Mar, 9-11; Salzburg.
[Oral Communication]
Ludvik, B; Ebenbichler, C; Paulweber, B; Toplak, H; Brath, H; Prager, R
Hypoglycaemia among insulin-treated patients with diabetes: Austrian results from the international hypoglycaemia assessment tool (HAT) study
WIEN KLIN WOCHENSCHR. 2014; 126: S185-S186.
[Poster]
Web of Science
Toplak, H
Where are the anti-obesity drugs in Europe ? Future Strategies.
A position statement from the EASO OMTF.
European Congress on Obesity 2014; May 28-31, 2014; Sofia. 2014.
[Oral Communication]
Toplak, H
Clinical value of hydration for obesity management.
European Congress on Obesity 2014; May 28-31, 2014; Sofia. 2014.
[Oral Communication]
Feitek, D; Kastner, P; Toplak, H; Pail, E;
Pilot Study: "Feasibility and Acceptance of a tele-dietetic Intervention in Patients with Type-2-Diabetes mellitus without Insulin Therapy".
WIEN KLIN WOCHENSCHR. . 2013; 125(17-18):545-545.
[Poster]
Web of Science
Gäbler, G; Toplak, H; Hefti, R; Pail, E
The relationship between lifestyle factors and religiosity/spirituality.
DIETS2/EFAD Conference VII. Non-communicable Diseases - the dietitians´response to Health 2020.; Nov 8-9, 2013; Garda, Italy. 2013.
[Poster]
Galler, M; Konrad, M; Grach, D; Toplak, H; Pail, E
Unterschiede im Ernährungsverhalten von Beschäftigten der regelmäßigen Wechselschicht im Vergleich zum unregelmäßigen Schichtdienst am Beispiel der Versicherten der Versicherungsanstalt für Eisenbahnen und Bergbau.
16. Wissenschaftliche Tagung der Österreichischen Gesellschaft für Public Health: Forschung und Anwendung; Jun 19-20, 2013; St. Pölten. 2013.
[Poster]
Galler, M; Konrad, M; Grach, D; Toplak, H; Pail, E;
Differences in Nutrition Behavior between the regular rotating Shift Workers compared with the irregular Shift Workers, the Example of Persons insured with the Insurance Company for Railways and Mining.
WIEN KLIN WOCHENSCHR. . 2013; 125(17-18):547-547.
[Poster]
Web of Science
Haring, A; Roller-Wirnsberger, R; Neugebauer, H; Toplak, H; Pail, E;
What simple, practical Methods are appropriate in a clinical Setting for the Diagnosis of Sarcopenia in Elderly Patients who have fallen?.
WIEN KLIN WOCHENSCHR. . 2013; 125(17-18):564-564.
[Poster]
Web of Science
Tomaschitz, A; Grammer, T; Pilz, S; Meinitzer, A; Rus-Machan, J; Pieske, B; Toplak, H; Kraigher-Krainer, E; März, W.
Amino acid profile, glucose homeostasis and risk of
cardiovascular death in type 2 diabetes
http://www.oedg.org/pdf/1311_JT_Hauptprogramm.pdf. 2013; -41. Jahrestagung der ÖDG; NOV 21-23, 2013; Salzburg, AUSTRIA.
[Oral Communication]
Tomaschitz, A; Meinitzer, A; Pieske, B; März, W; Fahrleitner-Pammer, A; Grammer, T; Kraigher-Krainer, E; Toplak, H; Pilz, S.
Association of Tryptophan Metabolism with Metabolic
Traits in Hypertensive Patients
http://www.oedg.org/pdf/1311_JT_Hauptprogramm.pdf. 2013; -41. Jahrestagung der ÖDG; 21.-23. November 2013; Salburg, AUSTRIA.
[Poster]
Toplak, H; Rossner, S; Dvorak, R
Effects of phentermine and topiramate extended-release (PHEN/TPM ER) on weight loss (WL) and glycaemic parameters by gender, race, and baseline body mass index (BMI)
DIABETOLOGIA. . 2013; 56: S259-S259.-49th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD); SEP 23-27, 2013; Barcelona, SPAIN.
[Poster]
Web of Science
Tomaschitz A; Meinitzer, A; Pieske, P; Kienreich, K; März, W; Ritz, E; Fahrleitner-Pammer, A; Grammer, T; Kraigher-Krainer, E; Colantonio, C; Toplak, H; Drechsle, C; Verheyen, N; Pilz, S
Associations of Tryptophan Metabolism with Metabolic Traits in Hypertensive Patients: the Graz Endocrine Causes of Hypertension (GECOH) Study
Abstraktband. 2012; -Biomarkers in Heart Failuren with Preserved Ejection Fraction - International Symposium; OCT 13-15, 2012; Graz, AUSTRIA.
[Poster]
Maierhofer, S; deCampo, A; Stojakovic, T; Jahnel, H; Toplak, H
EFFECTIVITY OF COLESEVELAM IN STATIN INTOLERANT PATIENTS ± EZETIMIBE.
ATHEROSCLER SUPPL. 2011; 12(1):163-163.-79th Congress of the European Atherosclerosis Society (EAS); JUN 26-29, 2011; Gothenburg, SWEDEN.
Doi: 10.1016/S1567-5688(11)70779-6
[Poster]
Web of Science
FullText
FullText_MUG
Ederer, T; Toplak, H; Obermayer-Pietsch, B; Hammer, H; Hogenauer, C
Diagnosis of lactose intolerance - Comparison of the genetic tests for primary adult lactase deficiency with lactose H2 breath test.
WIEN KLIN WOCHENSCHR. 2010; 122(17-18): A10-A10.
Web of Science
Fliesser-Gorzer, E; Kellner, A; Toplak, H
A Comparison of obese and Diabetic Patients regarding Weight Loss, Body Composition Measurement, Blood Glucosa Control and cardiovascular Risk Factors, between conventional Diet and the VLCD Program INSUmed
WIEN KLIN WOCHENSCHR. 2010; 122(19-20): A45-A45.
[Poster]
Web of Science
Abrahamian, H; Hofmann, P; Prager, R; Toplak, H
Diabetes mellitus and co-morbid depression: treatment with Milnacipran results in significant improvement of both diseases
INT J PSYCHIATR CLIN PRACT. 2009; 13: 23-23.
[Poster]
Web of Science
Toplak, H
Der diabetische Fuß - eine interdisziplinäre Herausforderung. Diabetologische Intervention.
37. Jahrestagung der österreichischen Diabetesgesellschaft; November 19-21, 2009; Salzburg. 2009.
[Oral Communication]
FullText
Toplak, H
Langzeittherapie mit Antiadiposita
10. Jahrestagung der Österreichischen Adipositasgesellschaft; Oct 30-31; Seggau, Austria. 2009.
[Oral Communication]
Toplak, H
The role of physical activity in obesity management.
2nd Central European Congress on Obesity (CECON); October 1-3, 2009; Budapest, Hungary. 2009.
[Oral Communication]
FullText
Toplak, H
Weight control and cardiovascular risk in patients with type 2 diabetes.
EASO/IOMTF Obesity Course; June 11-13, 2009; Kiew, Ukraine. 2009.
[Oral Communication]
Toplak, H
Metabolic Syndrome.
EASO/IOMTF Obesity Course; June 11-13, 2009; Kiew, Ukraine. 2009.
[Oral Communication]
Toplak, H
Welche Zusammenhänge bestehen zwischen Depression und Diabetes mellitus Typ 2 ? Zusammenhänge auf Stoffwechselebene - Implikationen für therapeutische Maßnahmen.
5. ÖGAM Jahrestagung; Juni 25-27, 2009; Wien, Österreich. 2009.
[Oral Communication]
Toplak, H
Multifaktorielle Therapie des Typ 2 Diabetes.
Jahrestagung der Steirischen Diabetesgesellschaft; Juni 27, 2009; Graz, Österreich. 2009.
[Oral Communication]
Toplak, H
Pharmacological options for synergistically treating diabetes and obesity.
EASO/IOMTF Obesity Course; June 11-13, 2009; Kiew, Ukraine. 2009.
[Oral Communication]
Toplak, H
Neue Prognosen, neue Risikoeinschätzungen. Lifestyleerkrankung Adipositas: Folgen und Prognose.
Kongress Versicherungsmedizin; März 12, 2009; Wien, Österreich. 2009.
[Oral Communication]
TOPLAK, H
Lifestyle versus Phamracotherapy in obesity management.
2nd Polish Congress on Obesity; October 15-17, 2009; Szczecin (Stettin), Poland. 2009.
[Keynote lecture]
Haslinger, S; Toplak, H; Dimai, H; Erwa, W
Research on the breakdown point of extra long chain of fatty acids in patients with known to have adrenal insufficiency
WIEN KLIN WOCHENSCHR. 2008; 120(15-16):A41-A41.-Austrian Association of Internal Medicine; 17th-20th September 2008; Graz, Austria.
[Poster]
Web of Science
Kapp, C; Fliesser-Gorzer, E; Toplak, H
Sarcopenia adiposity: Differences in a weight loss in comparison with over weighted with a normal muscle mass
WIEN KLIN WOCHENSCHR. 2008; 120(15-16):A39-A39.-Austrian Association of Internal Medicine; 17th-20th September 2008; Graz, Austria.
[Poster]
Web of Science
Toplak, H
Incretin-based strategies for the treatment of type 2 diabetes mellitus.
MSD European speaker forum; Feb 2; Istanbul. 2008.
[Oral Communication]
Toplak, H
Management des Metabolischen Syndroms nach Schlaganfall
Neurorehabilitation 2008; December 4-6; Wien. 2008.
[Oral Communication]
Toplak, H
The brain as a therapeutical target of insulin.
Diagnosing and Treating Diabesity; October 2-4; Santiago de Compostella, Spain. 2008.
[Oral Communication]
Toplak, H
Lipide, endotheliale Dysfunktion und Blutdruck
keine2008; -Jahrestagung der Österreichischen Adipositasgesellschaft; October 24-26, 2008; Seggau.
[Keynote lecture]
Toplak, H
Atherosklerose beim Typ II Diabetiker - Wo liegen die Ursachen ?
24. Frühjahrstagung der Österreichischen Diabetesgesellschaft (ÖDG); Mai 30-31; Bad Aussee. 2008.
[Oral Communication]
Toplak, H
GLP-1 im Focus der Diabetes-Forschung
24. Frühjahrstagung der Österreichischen Diabetesgesellschaft (ÖDG); Mai 30-31; Bad Aussee. 2008.
[Oral Communication]
Toplak, H
Antiadiposita - Einfluss auf das Diabetesrisiko
Jahrestagung der Österreichischen Diabetesgesellschaft; November 20-22, 2008; Innsbruck, Austria. 2008.
[Oral Communication]
FullText
Toplak, H
Fat or fit
none2008; -Controversies on Obesity, Diabetes and Hypertension; October 30th-November 2nd, 2008; Barcelona.
[Keynote lecture]
Toplak, H
Pharmakotherapie der Adipositas
keine2008; -Deutsche Adipositastagung - SCOPE Kurs; 16. Oktober 2008; Freiburg, Deutschland.
[Keynote lecture]
Toplak, H
Behavioral and practical lifestyle approaches in obesity management
none2008; -1st Central European Congress on Obesity; September 25-27, 2008; Karlovy Vary.
[Keynote lecture]
Toplak, H
Modern Therapeutic Approach of Global Cardiovascular Risk
2nd Serbian Congress on Hyperlipidemia; September 18, 2008; Novi Sad. 2008.
[Keynote lecture]
TOPLAK, H
Sitagliptin the first DPP-4 inhibitor- Efficacy in HbA1C reduction without compromise
NONE2008; -The 7th National Congress of the Romanian Federation of Diabetes, Nutrition, Metabolic diseaseS; November, 5 7 2008; Sibiu, Romania.
[Keynote lecture]
Fließer-Görzer, E; Tscherner, D; Toplak, H
Effekt einer VLCD unter Anwendung des INSUmed-Programmes auf die Fettmasse bei Patienten ab einem BMI >= 29, im Vergleich zu gewichtsgematchten Diabetikern.
Jahrestagung der Österreichischen Adipositasgesellschaft; Oct 19-21; Seggau. 2007.
[Poster]
Gorzer, E; Wamser, K; Tscherner, D; Toplak, H
The effect of a VLCD programme using INSUmed on fat mass in patients with BMI above 29 - a comparison of type 2 diabetic and non diabetic patients
INT J OBESITY. 2007; 31: S166-S166.
[Poster]
Web of Science
Toplak, H
Medikamente und Adipositas. Antidiabetika.
8. Jahrestagung der Österreichischen Adipositasgesellschaft; Oct 19-21; Seggau. 2007.
[Oral Communication]
Toplak, H
Die Fettzelle als endokrines Organ.
38. Kongress für Allgemeinmedizin; Nov 22-24; Graz. 2007.
[Oral Communication]
Toplak, H
Metabolisches Syndrom. Metabolische Zusammenhänge - Grundlagen: Aktuelle Kriterien der Diagnostik und Zielwerte
24. Ernährungskongress der Diaetologen Österreichs. ; Mär 15-16; Wien. 2007.
[Oral Communication]
Toplak, H
Adipositas- State of the art. 10 Jahre Österreichische Adipositasgesellschaft.
38. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; Sept 27-29; Innsbruck. 2007.
[Oral Communication]
Toplak, H
Neue Therapieoptionen bei Adipositas und Metabolischem Syndrom.
Österreichische Gesellschaft für Allgemeinmedizin Wintertagung.; Jan 17-19; Zug, Arlberg. 2007.
[Oral Communication]
Toplak, H
Innovationen in der Diabetestherapie.
Wissenschaftliche Gesellschaft der Ärzte in der Steiermark; Jan 25; Graz. 2007.
[Oral Communication]
Toplak, H
Guidelines der Lipidtherapie 2007.
"Management der Hyperlipidaemien"
AG Rehabilitation der Österreichischen Kardiologischen Gesellschaft; Apr 27; RZ Hochegg. 2007.
[Oral Communication]
Toplak, H
Sitagliptin - First in the new class of DPP-IV inhibitors: Efficacy in clinical trials.
6 th congress of the Romanian Federation of Diabetes, Nutrition, Metabolic Diseases.; Nov 7-9; Cluj, Napoca. 2007.
[Oral Communication]
Toplak, H
Athiopathogenesis of Obesity.
6th International Postgraduate Course Obesity and Type 2 Diabetes mellitus. Hellenic Association for the Study of Obesity, Metabolism and Eating disorders.; May 11-12; Athens, Greece. 2007.
[Keynote lecture]
Toplak, H
Das Metabolische Syndrom. Warum Medikamente vor Lifestyle ?
Wolfsberger Präventionstage ; Oct 5-6; Wolfsberg. 2007.
[Oral Communication]
Toplak, H
Metabolisches Syndrom: Viszerales Fett.
Zentrale Fortbildungstagung der Österreichischen Apothekerkammer.; Nov 17-18; Wien. 2007.
[Oral Communication]
Toplak, H
The evidence of lowering LDL-C is clear, however: Target values and realtity in Austria. Initiatives for a consequent omplementation of target values.
Austrian Baltic Cardiology Update; June 7-8; Vilnius, Lithuania. 2007.
[Oral Communication]
Toplak, H
Risikofaktor Rauchen bei Diabetikern.
Jahrestagung der Österreichischen Diabetesgesellschaft (ÖDG).; Nov 29-31; Innsbruck. 2007.
[Oral Communication]
Toplak, H
Kardiale Effekte der Adipositas.
Jahrestagung der Österreichischen Diabetesgesellschaft (ÖDG).; Nov 29-31; Innsbruck. 2007.
[Oral Communication]
Toplak, H
Inkretine und DPP-IV Hemmer: Innovative Therapie des Typ 2 Diabetes.
23. Frühjahrstagung der Österreichischen Diabetesgesellschaft.; Apr 20; Eisenstadt. 2007.
[Oral Communication]
Toplak, H
Obesity and the Metabolic syndrome.
"Metabolic syndrome in clinical practice"
ECO 2007 Pre-congress Satellite Symposium; Apr 20-21; Cluj, Napoca, Romania. 2007.
[Oral Communication]
Toplak, H
Abdominal obesity: innocent bystander or a serious risk factor for cardiovascular disease ?
Europrevent 2006; May 11-13, 2006; Athens. 2006.
[Oral Communication]
FullText
Toplak, H
Drug-induced weight gain in depression - can it be avoided ? The internist´s perspective.
1st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHY); October 26-28, 2006; Berlin. 2006.
[Oral Communication]
FullText
Toplak, H
Antiadiposita - Einfluss auf das Diabetesrisiko.
Österreichische Diabetestagung; Nov 16-18, 2006; Innsbruck. 2006.
[Oral Communication]
FullText
Toplak, H
Auswirkungen der Insulintherapie mit neuen Insulinen auf die Teilkomponenten des Metabolischen Syndromes.
Österreichische Diabetestagung; Nov 16-18, 2006; Innsbruck. 2006.
[Oral Communication]
FullText
Toplak, H
Obesity is the epidemic of the century. Can we agree on what is the best way to achieve weight loss ? Behavior and Lifestyle Therapy versus Pharmacotherapy.
1st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHY); October 26-28, 2006; Berlin. 2006.
[Oral Communication]
FullText
Toplak, H
What is obesity ? Is obesity of importance ? What are the dynamics of weight gain/ loss ?
1st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHY); October 26-28, 2006; Berlin. 2006.
[Oral Communication]
FullText
Toplak, H
Stellenwert von Formuladiäten.
Jahrestagung der Österreichischen Adipositasgesellschaft; Nov 3-5, 2006; Seggau. 2006.
[Oral Communication]
FullText
Toplak, H
Erstmanifestation Zuckerkrankheit - was erwartet uns bei den Blutfetten ?
Österreichische Diabetestagung; Nov 16-18, 2006; Innsbruck. 2006.
[Oral Communication]
FullText
Toplak, H
Acomplia® - eine neue Therapieoption für den übergewichtigen/ adipösen Typ-2- Diabetiker
Österreichische Diabetestagung; Nov 16-18, 2006; Innsbruck. 2006.
[Oral Communication]
FullText
Toplak, H
Zielwerte in der Lipidtherapie bei koronarer Herzkrankheit: LDL-Cholesterin
Österreichische Internistentagung 2006; Sep 28-20, 2006; Baden. 2006.
[Oral Communication]
FullText
Toplak, H
Ist Gewichtszunahme durch Psychopharmaka aus internistischer sicht vertretbar ?
XII. Update Psychiatrie; June 22-23, 2006; Vienna. 2006.
[Oral Communication]
FullText
Jacob, S; Ziegler, O; Toplak, H
Orlistat improves all components of the metabolic syndrome in overweight and obese patients on two diets
INT J OBESITY 2004 28: S154-S154.
Web of Science
Keinrath, P; Mellitzer, K; Toplak, H
Body fat mass and waist circumference increase postprandial lipemia in obese premenopausal women.
INT J OBESITY. 2004; 28 Suppl 3: S54-S54.-13th European Congress on Obesity; MAY 26-29, 2004; Prague, CZECH REPUBLIC.
Web of Science
PubMed
Mellitzer, K; Keinrath, P; Toplak, H
Endothelial function following an oral fat load in obese premenopausal women.
INT J OBESITY. 2004; 28 Suppl 4(S1):S22-S22.-13th European Congress on Obesity; MAY 26-29, 2004; Prague, CZECH REPUBLIC.
Web of Science
PubMed
Toplak, H; Vercruysse, F; Sun, X; Fitchet, M
Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
INT J OBESITY 2004 28: S159-S159.
Web of Science
Hoegenauer, C; Hammer, HF; Mellitzer, K; Renner, W; Toplak, H
Evaluation of a new genetic test compared to lactose hydrogen breath test for the diagnosis of acquired primary lactase deficiency
GASTROENTEROLOGY. 2003; 124(4): A64-A64.
Doi: 10.1016/S0016-5085(03)80315-3
Web of Science
FullText
FullText_MUG
Toplak, H; Sharma, AM; Van Gaal, L
Rapid weight loss with orlistat plus diet after 12 weeks of treatment
OBES RES 2001 9: 188S-188S.
Web of Science
Winklhofer-Roob, BM; Jerlich, A; de Campo, A; Roob, JM; Schaur, RJ; Toplak, H; Paulweber, B
LDL susceptibility to copper- and hypochlorite-mediated oxidation in familial defective apolipoprotein B-100 (FDB).
FASEB J 2000 14: A521-A521.
Web of Science
Schallmoser, K; de Campo, A; Schmidt, H; Kostner, GM; Toplak, H
Familiäre Hypercholesterinämie (LDL-Rezeptor-Mutation-Graz)-eine Familienanalyse.
Abstraktband.1997; -Jahrestagung der Österreichischen Atherosclerosegesellschaft,; 1997; Dürnstein, Austria.
[Oral Communication]
Wallner, S; Watzinger, N; Lindschinger, M; Wascher, TC; Toplak, H; Smolle, KH; Elmadfa, I; Eber, B; Klein, W; Krejs, GJ
Effects of intensified lifestyle modification on clinical restenosis after coronary angioplasty
ATHEROSCLEROSIS 1997 134: 268-268.
Doi: 10.1016/S0021-9150(97)89410-5
Web of Science
FullText
FullText_MUG
Wascher, TC; HabersackWallner, S; Bahadori, B; Roden, M; Novotny, P; Toplak, H
Effects of melatonin supplementation on plasma leptin levels.
DIABETOLOGIA 1997 40: 1064-1064.
Web of Science
Wascher, TC; Stollberger, R; Pammer, R; Wallner, S; Toplak, H
Forearm composition determines peak reactive hyperemia and flow debt repayment in healthy subjects
ATHEROSCLEROSIS 1997 134: 95-95.
Doi: 10.1016/S0021-9150(97)88548-6
Web of Science
FullText
FullText_MUG
HabersackWallner, S; Kreuz, E; Graier, WF; Bahadori, B; Toplak, H; Wascher, TC
Superoxide scavenging effects of free aminoacids
DIABETOLOGIA 1996 39: 855-855.
Web of Science
Habersack-Wallner, S; Lindschinger, M; Krachler, M; Toplak, H; Watzinger, N; Klein, W; Elmadfa, I
Spurenelementstatus und Aktivität antioxidativer Enzyme bei Patienten mit koronarer Herzkrankheit und PTCA - eine Analyse.
Acta Medica Austriaca. 23(S1):34-34.-Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; Linz.
Wascher, TC; Bahadori, B; Toplak, H
Effects of L-arginine on insulin sensitivity and insulin mediated vasodilation in NIDDM.
DIABETES. 1996; 45: 571-571.
Web of Science
Wascher, TC; Graier, WF; Bahadori, B; Toplak, H
Effects of L-arginine on insulin-mediated vasodilation and insulin sensitivity in NIDDM and obesity.
DIABETOLOGIA 1996 39: 575-575.
Web of Science
WASCHER, TC; GRAIER, WF; BAHADORI, B; TOPLAK, H
L-ARGININE IMPROVES INSULIN-RESISTANCE IN OBESE PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS
DIABETOLOGIA 1995 38: A158-A158.
Web of Science
TOPLAK, H; WASCHER, TC; GRUBENTHAL, I; DITTRICH, P; GRAIER, WF; KREJS, GJ
AMINOGUANIDINE REESTABLISHES VASCULAR ENDOTHELIAL-CELL REPARATIVE POTENCY UNDER HYPERGLYCEMIC CONDITIONS
DIABETOLOGIA. 1994; 37: A54-A54.
Web of Science
WASCHER, TC; BACHERNEGG, M; STARK, G; TOPLAK, H; DITTRICH, P; GRAIER, WF; KREJS, GJ
VASODILATION INDUCED BY SLIGHT HYPOXIA UNDER HYPERGLYCEMIC CONDITIONS DEPENDS ON THE AVAILABILITY OF L-ARGININE
DIABETOLOGIA. 1994; 37: A23-A23.
Web of Science
PIEBER, TR; SEMLITSCH, B; SCHNEDL, WJ; BRUNNER, GA; TOPLAK, H; SAGMEISTER, EM; SCHATTENBERG, S; KREJS, GJ
EVALUATION OF A 5-DAY OUTPATIENT TEACHING PROGRAM FOR INTENSIFIED INSULIN THERAPY - A 3 YEAR FOLLOW-UP
DIABETOLOGIA. 1993; 36: A158-A158.
Web of Science
WASCHER, TC; LACKNER, L; TOPLAK, H; GRAIER, WF
MECHANISMS OF GLUCOSE-MEDIATED INCREASES IN THE FORMATION OF ENDOTHELIUM-DERIVED-RELAXING-FACTOR
DIABETOLOGIA. 1993; 36: A12-A12.
Web of Science
TOPLAK, H; HALLER, EM; LAUERMANN, T; TILZ, GP; WEBER, K; SCHNEDL, W; WASCHER, T; HAAS, A; SCHMUT, O
INCREASED RISK FOR ACTIVE CHLAMYDIA INFECTION IN TYPE-II DIABETES-MELLITUS
DIABETOLOGIA. 1992; 35: A142-A142.
Web of Science
WEBER, K; STIEGLER, C; TOPLAK, H; SCHNEDL, W; LEB, G; KREJS, GJ
PREDICTING RISK OF OSTEOPOROSIS SUBSEQUENT TO REDUCED BONE-FORMATION IN FEMALE JUVENILE DIABETICS BY MEASUREMENT OF PEAK BONE MASS
DIABETOLOGIA. 1992; 35: A192-A192.
Web of Science
BATCHIULIS, V; TOPLAK, H; WIESMANN, U
EFFECT OF CYCLOSPORINE-A (CSA) AND VERAPAMIL ON MEMBRANE FLUIDITY OF CULTURED HUMAN SKIN FIBROBLASTS (HSF)
PEDIAT RES. 1990; 28(3): 285-285.
Doi: 10.1203/00006450-199009000-00075
Web of Science
FullText
FullText_MUG
BATCHIULIS, V; TOPLAK, H; LUTHY, C; WIESMANN, U; OETLIKER, O
RESPONSE OF PROSTAGLANDIN (PG) SYNTHESIS AND MEMBRANE FLUIDITY TO CHANGES OF OSMOLALITY IN CULTURED HUMAN-SKIN FIBROBLASTS (HSF)
PEDIAT RES. 1988; 24(2): 270-270.
Doi: 10.1203/00006450-198808000-00087
Web of Science
FullText
FullText_MUG
TOPLAK, H; HERMETTER, A; WIESMANN, UN
INSITU FLUORESCENCE ANISOTROPY MEASUREMENTS IN CULTURED-CELLS BY A COVERSLIP TECHNIQUE USING 1-(4-TRIMETHYLAMMONIUMPHENYL)-6-PHENYL-1, 3, 5-HEXATRIENE (TMA-DPH)
PEDIAT RES. 1988; 24(2): 270-270.
Doi: 10.1203/00006450-198808000-00084
Web of Science
FullText
FullText_MUG
TOPLAK, H; HERMETTER, A; HONEGGER, U; WIESMANN, U
MEMBRANE FLUIDITY - A NEW BIOPHYSICAL METHOD FOR STUDIES OF DRUG EFFECTS IN HUMAN-FIBROBLASTS
PEDIAT RES. 1987; 22(2): 217-217.
Doi: 10.1203/00006450-198708000-00023
Web of Science
FullText
FullText_MUG